RBC Capital analyst Leonid Timashev downgraded Exelixis (EXEL) to Sector Perform from Outperform with a price target of $50, up from $45. The firm believes the shares at current levels are fairly valuing the remaining branded Cabometyx cash flows and probability weighted life-cycle potential ahead of the 2031 patent cliff. RBC wants to see additional life cycle success that can offset the loss of Cabometyx before again recommending shares of Exelixis.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXEL:
- Exelixis downgraded to Sector Perform from Outperform at RBC Capital
- Truist biotech analyst holds an analyst/industry conference call
- Exelixis price target raised to $53 from $47 at H.C. Wainwright
- Exelixis’s Promising STELLAR-303 Trial Results Lead to Buy Rating and Increased Approval Probability
- NuScale, Hims & Hers, Snowflake, Advance Auto Parts, Exelixis: Trending by Analysts